Paradigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%

MT Newswires Live

Nov 17, 2025

Paradigm Biopharmaceuticals (ASX:PAR) has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.

Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.

The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.

Shares of the company rose 7% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584661528"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584661528\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584661528?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 12:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584661528","market":"sg","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.</p><p>Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.</p><p>The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.</p><p>Shares of the company rose 7% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Withdraws About $5 Million From Convertible Note Facility; Shares Rise 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-17 12:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.</p><p>Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.</p><p>The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.</p><p>Shares of the company rose 7% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584661528","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584661528","pubTimestamp":1763352307,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.Shares of the company rose 7% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PAR.AU":"PARADIGM BIOPHARMACEUTICALS","BK7508":"医药生物股"},"translate_title":"Paradigm Biopharmaceuticals从可转换票据融资中提取约500万美元；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) has withdrawn about $5 million from its $27 million Convertible Note Facility with Obsidian Global Partners, according to a Monday filing with the Australian bourse.Funds will be used as additional working capital for the company's phase three clinical trial, the filing said.The remaining $15 million in the facility will be used to support ongoing phase three activities, regulatory engagement, and commercial-readiness programs, the filing added.Shares of the company rose 7% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}